Healthcare Industry News: benzoyl peroxide
News Release - August 2, 2007
Obagi Medical Products' New Study Shows CLENZIderm M.D. is Clinically Effective in the Treatment of Acne at Both Once- and Twice-Daily Dosing
Poster Presented at Summer AAD in New York, August 2-4LONG BEACH, Calif.--(HSMN NewsFeed)--Obagi Medical Products, Inc. (Nasdaq:OMPI ), a leader in topical aesthetic and therapeutic skin health systems, announced today highlights from a clinical evaluation of its novel CLENZIderm M.D. Acne Therapeutic System at the Summer Meeting of the American Academy of Dermatology (AAD) taking place in New York, August 1-5.
This investigator blind, randomized study concluded that the CLENZIderm M.D. System gives physicians the flexibility to titrate between once-daily and twice-daily applications of the serum gel according to the sensitivity of an individual's skin while achieving a similar dramatic reduction in acne lesions in as quickly as two weeks. The CLENZIderm M.D. System consists of a solubilized, 5% benzoyl peroxide (BPO) serum gel and 2% salicylic acid-based cleanser and pore therapy. The novel, three-step CLENZIderm M.D. System is designed to enhance the efficacy of BPO through its SoluZyl(TM) penetrating technology.
This clinical evaluation looked at the complete three-part acne therapeutic system (including the cleanser as well as the serum gel and pore therapy) used either once a day, or titrating to twice a day. All regimens showed significant reductions in inflammatory and non-inflammatory lesions within only two weeks of treatment, with continued improvement through the three-week study duration. Inflammatory lesion reductions reached 47% and 44% for both once-per-day and twice-per-day applications, respectively, with reductions reaching 68% and 73%, respectively, by week three. Similar trends were also seen with non-inflammatory lesions reaching 43% and 49%, respectively, by week two, with continued improvement reaching 54% and 56%, respectively, by week three.
Rick Kozloski, Vice President Marketing & Dermatology of Obagi Medical Products, stated, "Physicians who are sensitive to the risks of antibiotic resistance will find CLENZIderm M.D. a welcome addition to their acne treatment arsenal. Patients who have found other acne treatments to be too harsh will welcome the ability of their physician to optimally titrate their dosage to balance tolerability with efficacy."
The results of previous studies have demonstrated that the CLENZIderm M.D. BPO serum gel alone penetrated into the pores and reduced P. acnes more readily than a generic BPO formulation. Further studies also have shown that the CLENZIderm M.D. System provides acne lesion reductions equal to or greater than a leading BPO/antibiotic combination without the use of antibiotics.
Steve Carlson, President and CEO of Obagi Medical Products, said, "We are very pleased with the growing body of clinical data we are compiling to support the efficacy and high patient satisfaction ratings of our therapeutic acne system. We continue to invest in research and development in order to bring to market new and novel, therapeutically oriented dermatological products."
The products in the study were well tolerated, and although some CLENZIderm users did experience transient stinging, the patients' average ratings never exceeded mild.
Posters will be available for viewing by meeting attendees on the 3rd Floor Promenade at the Hilton, New York, beginning at 7:00 a.m. on Thursday, August 2 through 5:00 p.m., Saturday August 4.
About Obagi Medical Products, Inc. (www.obagi.com)
Obagi Medical Products is a specialty pharmaceutical company focused on the aesthetic and therapeutic skin health markets. The company develops and commercializes prescription-based, topical skin health systems that enable physicians to treat a range of skin conditions, including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne and soft tissue deficits, such as fine lines and wrinkles. Obagi markets and sells physician-dispensed skin care systems directly to plastic surgeons, dermatologists and other physicians who are focused on aesthetic and therapeutic skin care. Obagi products are dispensed throughout the United States and in more than 35 other countries.
Forward Looking Statements
There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2006. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.
Source: Obagi Medical Products
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
